{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:57:17Z","timestamp":1770749837931,"version":"3.50.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,5,4]]},"DOI":"10.1080\/13543784.2022.2052042","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T09:52:35Z","timestamp":1647251555000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases"],"prefix":"10.1080","volume":"31","author":[{"given":"Hudson D.","family":"Stern","sequence":"first","affiliation":[{"name":"Retina Associates Ltd, IL, Elmhurst, USA"},{"name":"Division of Ophthalmology, Chicago, Cook County Health, IL, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rehan M","family":"Hussain","sequence":"additional","affiliation":[{"name":"Retina Health Institute, IL, Elgin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0063-5"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179441"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225300"},{"key":"cit0004","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1167\/iovs.18-26383","volume":"60","author":"Patel SS","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"cit0005","volume-title":"Basic and clinical science course, 2018-2019, retina and vitreous","author":"American Academy of Ophthalmology","year":"2019"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.014"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-015-0026-2"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.92"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1126\/science.2479986"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.mod.2019.103579"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.07.038"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009705200"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1667333"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S295223"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31820a67e4"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20140306-08"},{"key":"cit0018","unstructured":"Macugen FDA approval history. 2022. https:\/\/www.drugs.com\/history\/macugen.html. cited Feb 18, 2022."},{"issue":"5","key":"cit0019","first-page":"S103","volume":"26","author":"Baumal CR","year":"2020","journal-title":"Am J Manag Care"},{"key":"cit0020","unstructured":"Lucentis FDA approval history. 2022. https:\/\/www.drugs.com\/history\/lucentis.html. cited Feb 18, 2022."},{"key":"cit0021","unstructured":"Byooviz FDA approval history. 2022. https:\/\/www.drugs.com\/history\/byooviz.html. cited Feb 18, 2022."},{"key":"cit0022","unstructured":"U.S. Food and Drug Administration. FDA approves first biosimilar to treat macular degeneration disease and other eye conditions. September 17, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions. cited 2022 Feb 18"},{"key":"cit0023","unstructured":"Eylea FDA approval history. 2022. https:\/\/www.drugs.com\/history\/eylea.html. cited Feb 18, 2022."},{"key":"cit0024","unstructured":"Beovu SJ FDA approval history. 2022. https:\/\/www.drugs.com\/history\/beovu.html. cited 2022 Feb 18"},{"key":"cit0025","doi-asserted-by":"crossref","unstructured":"Where the newest anti-VEGF agent fits in the exudative-disease toolbox.Retina Specialist. November 26, 2019. https:\/\/www.retina-specialist.com\/article\/where-the-newest-antivegf-agent-fits-in-the-exudativedisease-toolbox. cited 2022 Feb 18","DOI":"10.1097\/01.NT.0000546412.05328.7c"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"cit0029","unstructured":"Susvimo SJ FDA approval history. 2022. https:\/\/www.drugs.com\/history\/susvimo.html. cited 2022 Feb 18"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.09.016"},{"key":"cit0031","author":"Genentech\u2019s HD","year":"2021","journal-title":"Ophthalmology Times"},{"key":"cit0032","unstructured":"Vabysmo SJ FDA approval history. 2022. https:\/\/www.drugs.com\/history\/vabysmo.html. cited 2022 Feb 18"},{"issue":"22","key":"cit0033","first-page":"00018","volume":"0140","author":"Wykoff CC","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"cit0034","first-page":"00010","volume":"0140","author":"Heier JS","year":"2022","journal-title":"Lancet"},{"key":"cit0035","unstructured":"Williams GA IVT injections: health policy implications. June 5, 2014. https:\/\/www.reviewofophthalmology.com\/article\/ivt-injections-health-policy-implications. cited 2022 Feb 18"},{"key":"cit0036","unstructured":"Market Scope: Novartis leads the race to launch a new anti-VEGF for wet AMD.EyeWire. October 1, 2019. https:\/\/eyewire.news\/articles\/market-scope-novartis-leads-the-race-to-launch-a-new-anti-vegf-for-wet-amd\/. cited 2022 Feb 18"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.062"},{"key":"cit0038","first-page":"1","volume":"13","author":"Chandrasekaran PR","year":"2021","journal-title":"Ther Adv Ophthalmol"},{"key":"cit0039","volume-title":"KODIAK Sciences","author":"Do DV","year":"2021"},{"key":"cit0040","unstructured":"Exploratory study to investigate the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics following single and multiple intravitreal administrations of KSI-301 in subjects with wAMD, DME and RVO. clinicaltrials.gov identifier: NCT03790852. Updated September 2, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03790852. cited 2022 Feb 18"},{"key":"cit0041","unstructured":"A study to evaluate the efficacy and safety of KSI-301, an anti-VEGF antibody biopolymer conjugate, versus aflibercept in Patients with neovascular (wet) age-related macular degeneration. (DAZZLE). ClinicalTrials.gov identifier: NCT04049266. Updated November 19, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04049266. cited 2022 Feb 18"},{"key":"cit0042","unstructured":"Kodiak Sciences Announces Top-Line Results from its initial Phase 2b\/3 Study of KSI-301 in patients with neovascular (Wet) age-related macular degeneration.PR Newswire. Published February 23, 2022. https:\/\/www.prnewswire.com\/news-releases\/kodiak-sciences-announces-top-line-results-from-its-initial-phase-2b3-study-of-ksi-301-in-patients-with-neovascular-wet-age-related-macular-degeneration-301488237.html. cited 2022 Mar 4"},{"key":"cit0043","unstructured":"Kodiak Sciences Announces First Quarter. Financial results and recent business highlights.PR newswire. May 10, 2021. https:\/\/www.prnewswire.com\/news-releases\/kodiak-sciences-announces-first-quarter-2021-financial-results-and-recent-business-highlights-301287302.html. cited 2022 Feb 19"},{"key":"cit0044","unstructured":"A study to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLIMMER). ClinicalTrials.gov identifier: NCT04603937. Updated Feb 16, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04603937. cited 2022 Feb 18"},{"key":"cit0045","unstructured":"A trial to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLEAM). clinicaltrials.gov identifier: NCT04611152.Updated September 2, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04611152. cited 2022 Feb 18"},{"key":"cit0046","unstructured":"A study to evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in patients with macular edema due to retinal vein occlusion (RVO) (BEACON). ClinicalTrials.gov identifier: NCT04592419.Updated August 23, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04592419. cited 2022 Feb 18"},{"key":"cit0047","unstructured":"A study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration (wAMD) (DAYLIGHT). ClinicalTrials.gov identifier: NCT04964089. Updated July 23, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04964089. cited 2022 Feb 18"},{"key":"cit0048","unstructured":"A study to evaluate the efficacy and safety of intravitreal KSI-301in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) (GLOW). ClinicalTrials.gov identifier: NCT05066230. Updated January 20, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05066230. cited 2022 Feb 18"},{"key":"cit0049","unstructured":"Adverum provides an update on ADVM-022 and the INFINITY trial in patients with diabetic macular edema. https:\/\/www.globenewswire.com\/news-release\/2021\/07\/22\/2267699\/32452\/en\/Adverum-Provides-Update-on-ADVM-022-and-the-INFINITY-Trial-in-Patients-with-Diabetic-Macular-Edema.html. Updated July 22, 2021. cited 2022 Feb 21"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2052042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T20:09:58Z","timestamp":1700338198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2052042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"alternative-id":["10.1080\/13543784.2022.2052042"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2052042","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}